Role of the Bronchodilator Test Defined by the Forced Vital Capacity in Chronic Obstructive Pulmonary Disease Phenotyping

References

• SinghD, AgustiA, AnzuetoA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease: the GOLD science committee report 2019. Eur Respir J. 2019;53(5):1900164. doi:10.1183/13993003.00164-201930846476
   PubMed Web of Science ®Google Scholar
• MathersCD, LoncarD. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. doi:10.1371/journal.pmed.003044217132052
   PubMed Web of Science ®Google Scholar
• VestboJ, AndersonW, CoxsonHO, et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J. 2008;31(4):869–873. doi:10.1183/09031936.0011170718216052
   PubMed Web of Science ®Google Scholar
• HanMK, AgustiA, CalverleyPM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi:10.1164/rccm.200912-1843CC20522794
   PubMed Web of Science ®Google Scholar
• BurgelPR, PaillasseurJL, CaillaudD, et al. Clinical COPD phenotypes: a novel approach using principal component and cluster analyses. Eur Respir J. 2010;36(3):531–539. doi:10.1183/09031936.0017510920075045
   PubMed Web of Science ®Google Scholar
• O’DonnellDE, ForkertL, WebbKA. Evaluation of bronchodilator responses in patients with “irreversible” emphysema. Eur Respir J. 2001;18(6):914–920. doi:10.1183/09031936.01.0021650111829096
   PubMed Web of Science ®Google Scholar
• SchermerT, HeijdraY, ZadelS, et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med. 2007;101(6):1355–1362. doi:10.1016/j.rmed.2006.09.02417098407
   PubMed Web of Science ®Google Scholar
• ChenC, JianW, GaoY, XieY, SongY, ZhengJ. Early COPD patients with lung hyperinflation associated with poorer lung function but better bronchodilator responsiveness. Int J Chron Obstruct Pulmon Dis. 2016;11:2519–2526. doi:10.2147/copd.S11002127785008
   PubMed Web of Science ®Google Scholar
• QuanjerPH, RuppelGL, LanghammerA, et al. Bronchodilator response in FVC is larger and more relevant than in FEV1 in severe airflow obstruction. Chest. 2017;151(5):1088–1098. doi:10.1016/j.chest.2016.12.01728040521
   PubMed Web of Science ®Google Scholar
• Exhaled NO. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med. 2005;171(8):912–930. doi:10.1164/rccm.200406-710ST15817806
   PubMed Web of Science ®Google Scholar
• MillerMR, HankinsonJA, BrusascoV, et al. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi:10.1183/09031936.05.0003480516055882
   PubMed Web of Science ®Google Scholar
• WangerJ, ClausenJL, CoatesA, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511–522. doi:10.1183/09031936.05.0003500516135736
   PubMed Web of Science ®Google Scholar
• MacintyreN, CrapoRO, ViegiG, et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J. 2005;26(4):720–735. doi:10.1183/09031936.05.0003490516204605
   PubMed Web of Science ®Google Scholar
• ZhengJ, ZhongN. Normative values of pulmonary function testing in Chinese adults. Chin Med J (Engl). 2002;115(1):50–54.11930658
   PubMed Web of Science ®Google Scholar
• PellegrinoR, ViegiG, BrusascoV, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968. doi:10.1183/09031936.05.0003520516264058
   PubMed Web of Science ®Google Scholar
• KunisakiKM, RiceKL, JanoffEN, RectorTS, NiewoehnerDE. Exhaled nitric oxide, systemic inflammation, and the spirometric response to inhaled fluticasone propionate in severe chronic obstructive pulmonary disease: a prospective study. Ther Adv Respir Dis. 2008;2(2):55–64. doi:10.1177/175346580808890219124359
   PubMedGoogle Scholar
• JarenbackL, ErikssonG, PetersonS, AnkerstJ, BjermerL, TufvessonE. Bronchodilator response of advanced lung function parameters depending on COPD severity. Int J Chron Obstruct Pulmon Dis. 2016;11:2939–2950. doi:10.2147/copd.S11157327932874
   PubMed Web of Science ®Google Scholar
• CerveriI, PellegrinoR, DoreR, et al. Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol (1985). 2000;88(6):1989–1995. doi:10.1152/jappl.2000.88.6.198910846010
   PubMed Web of Science ®Google Scholar
• BrindicciC, KharitonovSA, ItoM, et al. Nitric oxide synthase isoenzyme expression and activity in peripheral lung tissue of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;181(1):21–30. doi:10.1164/rccm.200904-0493OC19797159
   PubMed Web of Science ®Google Scholar
• YangX, TangX, CaoY, et al. The bronchiectasis in COPD-OSA overlap syndrome patients. Int J Chron Obstruct Pulmon Dis. 2020;15:605–611. doi:10.2147/copd.S24342932256061
   PubMed Web of Science ®Google Scholar
• LuZ, HuangW, WangL, XuN, DingQ, CaoC. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018;13:2695–2705. doi:10.2147/copd.S16578030214187
   PubMed Web of Science ®Google Scholar
• BrightlingCE, MonteiroW, WardR, et al. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2000;356(9240):1480–1485. doi:10.1016/s0140-6736(00)02872-511081531
   PubMed Web of Science ®Google Scholar
• SinghD, KolsumU, BrightlingCE, LocantoreN, AgustiA, Tal-SingerR. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. doi:10.1183/09031936.0016241425323230
   PubMed Web of Science ®Google Scholar
• LeighR, PizzichiniMM, MorrisMM, MaltaisF, HargreaveFE, PizzichiniE. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964–971. doi:10.1183/09031936.06.0007210516446316
   PubMed Web of Science ®Google Scholar
• DweikRA, BoggsPB, ErzurumSC, et al. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med. 2011;184(5):602–615. doi:10.1164/rccm.9120-11ST21885636
   PubMed Web of Science ®Google Scholar
• SoterS, BartaI, AntusB. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation. 2013;36(5):1178–1185. doi:10.1007/s10753-013-9653-823681903
   PubMed Web of Science ®Google Scholar
• GaoJ, ZhangM, ZhouL, et al. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:1287–1293. doi:10.2147/copd.S13499828490872
   PubMed Web of Science ®Google Scholar
• LazarZ, KelemenA, GalffyG, LosonczyG, HorvathI, BikovA. Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease. J Breath Res. 2018;12(3):036017. doi:10.1088/1752-7163/aac10a29813036
   PubMed Web of Science ®Google Scholar
• TangB, HuangD, WangJ, LuoLL, LiQG. Relationship of blood eosinophils with fractional exhaled nitric oxide and pulmonary function parameters in chronic obstructive pulmonary disease (COPD) exacerbation. Med Sci Monit. 2020;26:e921182. doi:10.12659/msm.92118232161254
   PubMed Web of Science ®Google Scholar
• DummerJF, EptonMJ, CowanJO, et al. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am J Respir Crit Care Med. 2009;180(9):846–852. doi:10.1164/rccm.200905-0685OC19661244
   PubMed Web of Science ®Google Scholar
• Alcazar-NavarreteB, Romero-PalaciosPJ, Ruiz-SanchoA, Ruiz-RodriguezO. Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes. Nitric Oxide. 2016;54:67–72. doi:10.1016/j.niox.2016.02.00326916083
   PubMed Web of Science ®Google Scholar
• Alcazar-NavarreteB, Ruiz RodriguezO, Conde BaenaP, Romero PalaciosPJ, AgustiA. Persistently elevated exhaled nitric oxide fraction is associated with increased risk of exacerbation in COPD. Eur Respir J. 2018;51(1):1701457. doi:10.1183/13993003.01457-201729348180
   PubMed Web of Science ®Google Scholar
• TakayamaY, OhnishiH, OgasawaraF, OyamaK, KubotaT, YokoyamaA. Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma-COPD overlap. Int J Chron Obstruct Pulmon Dis. 2018;13:2525–2532. doi:10.2147/copd.S16760030174422
   PubMed Web of Science ®Google Scholar
• DresselH, de la MotteD, ReichertJ, et al. Exhaled nitric oxide: independent effects of atopy, smoking, respiratory tract infection, gender and height. Respir Med. 2008;102(7):962–969. doi:10.1016/j.rmed.2008.02.01218396030
   PubMed Web of Science ®Google Scholar